PMID- 29614902
OWN - NLM
STAT- MEDLINE
DCOM- 20200130
LR  - 20220419
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
VI  - 32
IP  - 18
DP  - 2019 Sep
TI  - Intravenous immunoglobulin (IVIG) efficiency in women with common variable 
      immunodeficiency (CVID) decreases significantly during pregnancy.
PG  - 3092-3096
LID - 10.1080/14767058.2018.1455824 [doi]
AB  - Immunoglobulin replacement therapy, including intravenous immunoglobulin (IVIG), 
      is essential for pregnant women with common variable immunodeficiency (CVID) 
      since it prevents infection and improves the health of the newborn. There are no 
      established IVIG treatment protocols for pregnant women with CVID, and the 
      relationship between IVIG treatment and maternal serum IgG changes during 
      pregnancy remains unclear. Therefore, we reviewed the medical charts of four CVID 
      patients, including one receiving subcutaneous immunoglobulin (SCIG), for IVIG 
      dose and frequency, maternal serum IgG changes, obstetrical findings, and 
      perinatal outcomes. There were no serious infections but one abortion and all 
      patients continued therapy without IVIG-related adverse events. All eight 
      children born to the patients were healthy at one month. However, the IVIG 
      efficiency in those with CVID significantly decreased with progression of the 
      gestational period, suggesting that IVIG dose and frequency may be changed during 
      pregnancy to maintain stable serum IgG trough levels in women with CVID.
FAU - Egawa, Makiko
AU  - Egawa M
AD  - a Department of Pediatrics, Perinatal and Maternal Medicine , Tokyo Medical and 
      Dental University , Tokyo , Japan.
FAU - Kanegane, Hirokazu
AU  - Kanegane H
AD  - b Department of Pediatrics and Developmental Biology , Tokyo Medical and Dental 
      University , Tokyo , Japan.
FAU - Imai, Kohsuke
AU  - Imai K
AD  - a Department of Pediatrics, Perinatal and Maternal Medicine , Tokyo Medical and 
      Dental University , Tokyo , Japan.
FAU - Morio, Tomohiro
AU  - Morio T
AD  - b Department of Pediatrics and Developmental Biology , Tokyo Medical and Dental 
      University , Tokyo , Japan.
FAU - Miyasaka, Naoyuki
AU  - Miyasaka N
AD  - c Department of Comprehensive Reproductive Medicine , Graduate School of Medical 
      and Dental Sciences, Tokyo Medical and Dental University , Tokyo , Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20180403
PL  - England
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the 
      European Association of Perinatal Medicine, the Federation of Asia and Oceania 
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Administration, Intravenous
MH  - Adolescent
MH  - Adult
MH  - Common Variable Immunodeficiency/blood/*drug therapy
MH  - Female
MH  - Humans
MH  - Immunization, Passive/methods
MH  - Immunoglobulin G/blood
MH  - Immunoglobulins, Intravenous/*administration & dosage
MH  - Immunologic Factors/*administration & dosage
MH  - Pregnancy
MH  - Pregnancy Complications/blood/*drug therapy
MH  - Retrospective Studies
MH  - Young Adult
OTO - NOTNLM
OT  - Common variable immunodeficiency
OT  - immunoglobulin replacement therapy
OT  - pregnancy
EDAT- 2018/04/05 06:00
MHDA- 2020/01/31 06:00
CRDT- 2018/04/05 06:00
PHST- 2018/04/05 06:00 [pubmed]
PHST- 2020/01/31 06:00 [medline]
PHST- 2018/04/05 06:00 [entrez]
AID - 10.1080/14767058.2018.1455824 [doi]
PST - ppublish
SO  - J Matern Fetal Neonatal Med. 2019 Sep;32(18):3092-3096. doi: 
      10.1080/14767058.2018.1455824. Epub 2018 Apr 3.